Ceftriaxone is a third-generation cephalosporin antibiotic [1].
How do third-generation cephalosporins work?
Third-generation cephalosporins, like ceftriaxone, are characterized by their enhanced activity against Gram-negative bacteria compared to earlier generations [2]. They achieve this by inhibiting bacterial cell wall synthesis [3]. This class of antibiotics is generally more resistant to beta-lactamases, enzymes produced by bacteria that can inactivate these drugs [2].
What makes ceftriaxone different from other cephalosporins?
Ceftriaxone has a long half-life, allowing for once-daily dosing in many cases [4]. Its pharmacokinetic profile also permits high protein binding, which contributes to its prolonged duration of action [4]. This makes it effective for treating a broad range of bacterial infections, including meningitis, pneumonia, and gonorrhea [5].
When does ceftriaxone patent expiry occur?
Information regarding specific patents for ceftriaxone and their expiry dates is available through resources like DrugPatentWatch.com [6]. Patent expirations are crucial for the entry of generic versions of a drug into the market.
Are there alternatives to ceftriaxone?
Depending on the specific infection and local resistance patterns, alternative antibiotics may be used. These could include other cephalosporins, penicillins, or broader-spectrum antibiotics, often guided by susceptibility testing [7].
What clinical data supports ceftriaxone use?
Numerous clinical trials have demonstrated the efficacy and safety of ceftriaxone for various infections [5]. Its use is well-established in medical guidelines for treating susceptible bacterial pathogens [7].
What are common side effects of ceftriaxone?
Common side effects associated with ceftriaxone include injection site reactions, diarrhea, nausea, and rash [5]. More serious but rare side effects can include allergic reactions and changes in blood counts [5].
Can ceftriaxone be used in specific patient populations?
Ceftriaxone is frequently used in pediatric populations and can be administered to pregnant women when clearly needed, though its use in neonates requires careful consideration due to the risk of bilirubin displacement [5]. Dosage adjustments may be necessary in patients with severe liver or kidney impairment [5].
What are the regulatory approvals for ceftriaxone?
Ceftriaxone has received regulatory approval from agencies like the U.S. Food and Drug Administration (FDA) and is listed on the World Health Organization's List of Essential Medicines [5][8].
Sources:
[1] https://www.drugpatentwatch.com/content/what-generation-is-ceftriaxone
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841555/
[3] https://www.ncbi.nlm.nih.gov/books/NBK534782/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883047/
[5] https://pubchem.ncbi.nlm.nih.gov/compound/Ceftriaxone
[6] https://www.drugpatentwatch.com/
[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3127875/
[8] https://www.who.int/publications/i/item/9789240074181